Navigation Links
Resverlogix's Lead Drug Featured in Key Scientific Publication
Date:7/18/2008

RVX-208 is the only Apo-Al/HDL drug to be highlighted

TSX Exchange Symbol: RVX

CALGARY, July 18 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled "Emerging Antidyslipidemic Drugs", which appears in the current edition of Expert Opinion of Emerging Drugs, a well respected scientific journal for the pharmaceutical industry. The article written by Drs.' Pollex, Joy and Hegele provides an overview of current and upcoming dyslipidemic drugs.

"To be the only ApoA-l/HDL drug highlighted in an esteemed journal such as Expert Opinion of Emerging Drugs speaks volumes as to the excitement felt in the scientific community for our lead drug RVX-208," stated Donald McCaffrey, President and CEO of Resverlogix. "The data provided to the authors was our preclinical data. The Phase 1a data which we recently announced illustrated very similar trending as the African Green Monkey data of increased ApoA-I production and HDL functionality, thus our enthusiasm continues to build as we head into our Phase 1b/2a trial later this year."

RVX-208 is a first-in-class small molecule that facilitates endogenous ApoA-I production. It is positioned as one of the most promising emerging drugs in the treatment of atherosclerosis, the largest medical market in the world with a critical unmet need. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production. Consequently this raises functional HDL levels which in turn enhance reverse cholesterol transport, atherosclerosis regression and ultimately reduction of major adverse cardiovascular events (MACE).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. lifesDHA(TM) Featured in New Ricos(R) Cheese Sauce
2. Boydens Summit Practice Featured in the September Issue of New Jersey Business Magazine
3. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
4. Synvista Therapeutics to be Featured on Wallst.net
5. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
7. Marteks lifesDHA(TM) Now Featured in Two New Flavors of Rachels(R) Wickedly Delicious Yogurt from WhiteWave Foods
8. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
9. CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference
10. Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race
11. CT Laser Mammography Technology to be Featured at European Congress of Radiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... publication of a United States multicenter, prospective clinical study that demonstrates the ... diagnostic test capable of identifying clinically significant acute bacterial and viral respiratory ...
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):